Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database
Gérard et al.
, Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO..
, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2145
VigiBase retrospective showing a 20x increase in the risk of acute renal failure with remdesivir.[Gérard, Wu, Zhou]
show significantly increased risk of acute kidney injury with remdesivir.
Gérard et al., 19 Dec 2020, peer-reviewed, 8 authors.
Abstract: BRIEF REPORT
Remdesivir and Acute Renal Failure: A
Potential Safety Signal From Disproportionality
Analysis of the WHO Safety Database
Alexandre O. Gérard1,2, Audrey Laurain1, Audrey Fresse2, Nadège Parassol2, Marine Muzzone2,
Fanny Rocher2, Vincent L.M. Esnault1 and Milou-Daniel Drici2,*
Remdesivir is approved for emergency use by the US Food and Drug Administration (FDA) and authorized
conditionally by the European Medicines Agency (EMA) for patients with coronavirus disease 2019 (COVID-19).
Its benefit-risk ratio is still being explored because data in the field are rather scant. A decrease of the creatinine
clearance associated with remdesivir has been inconstantly reported in clinical trials with unclear relevance.
Despite these uncertainties, we searched for a potential signal of acute renal failure (ARF) in pharmacovigilance
postmarketing data. An analysis of the international pharmacovigilance postmarketing databases (VigiBase) of
the World Health Organization (WHO) was performed, using two disproportionality methods. Reporting odds ratio
(ROR) compared the number of ARF cases reported with remdesivir, with those reported with other drugs prescribed
in comparable situations of COVID-19 (hydroxychloroquine, tocilizumab, and lopinavir/ritonavir). The combination
of the terms “acute renal failure” and “remdesivir” yielded a statistically significant disproportionality signal with
138 observed cases instead of the 9 expected. ROR of ARF with remdesivir was 20-fold (20.3; confidence interval
0.95 [15.7–26.3], P < 0.0001]) that of comparative drugs. Based on ARF cases reported in VigiBase, and despite
the caveats inherent to COVID-19 circumstances, we detected a statistically significant pharmacovigilance signal
of nephrotoxicity associated with remdesivir, deserving a thorough qualitative assessment of all available data.
Meanwhile, as recommended in its Summary of Product Characteristics, assessment of patients with COVID-19 renal
function should prevail before and during treatment with remdesivir in COVID-19.
WHAT IS THE CURRENT KNOWLEDGE ON THE
Remdesivir is a nucleoside analog recently approved
by the US Food and Drug Administration (FDA) for emergency use and conditionally authorized by the European
Medicines Agency (EMA) in patients with coronavirus
disease 2019 (COVID-19), although data pertaining to
its effectiveness and safety are scant. A decrease of the
creatinine clearance has been reported inconstantly in clinical
WHAT QUESTION DID THIS STUDY ADDRESS?
Is there a potential signal of a risk of acute renal failure associated with remdesivir in pharmacovigilance postmarketing
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
There is a statistically suggestive disproportionality signal
regarding the association of acute renal failure and remdesivir.
This possible signal stood out when calculating the reporting odds ratio compared with 3 drugs used in patients with
COVID-19. However, many confounding factors persist.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
These results raise awareness about a possible pharmacovigilance signal regarding the risk of acute renal failure associated
with remdesivir, currently being qualitatively explored by regulatory agencies. Meanwhile, close serum creatinine monitoring
seems warranted in patients treated with remdesivir.
Remdesivir is an antiviral prodrug belonging to the adenosine
nucleoside analog family, which is..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.